Cancer Patient Remote Monitoring for Timely Communication Study

Launched by ASKLEPIOS PRORESEARCH · Sep 30, 2024

Keywords

ClinConnect Summary

This clinical trial, called the Cancer Patient Remote Monitoring for Timely Communication Study, is looking into how remote monitoring can help patients with advanced lung cancer (specifically stage IV non-small cell lung cancer or inoperable mesothelioma) during their treatment with immunotherapy. Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. In this study, patients will receive either a specific type of immunotherapy alone or in combination with chemotherapy, based on what their doctor thinks is best. Participants will use a mobile app to answer daily questions about their health and any side effects they may experience, which will help the healthcare team keep track of their well-being between clinic visits.

To join this study, patients must be at least 18 years old, have a good performance status (meaning they can carry out daily activities with minimal assistance), and have a life expectancy of more than six months. They should also be comfortable using a smartphone and a wearable device to monitor their health. It's important to note that this trial is not yet recruiting participants, but it represents an opportunity for patients to receive close monitoring and support during their treatment journey.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Signed Informed Consent Form
• • Age \> 18 years at the time of study entry
• • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
• • Life expectancy \> 6 months
• • Patient is able and willing to use smart phone and a wearable device/technology/sensor
• Exclusion Criteria:
• • Previous systemic treatment for metastatic or locally advanced disease